58381-23-0

Usage

Chemical Properties

Yellow Oil

InChI:InChI=1/C28H30O6/c1-21(29)33-28-27(32-19-24-15-9-4-10-16-24)26(31-18-23-13-7-3-8-14-23)25(34-28)20-30-17-22-11-5-2-6-12-22/h2-16,25-28H,17-20H2,1H3/t25-,26-,27-,28?/m1/s1

Upstream product

• 64363-77-5 methyl 2,3,5-tri-O-benzyl-D-ribofuranoside 
• 1824-96-0 methyl ribofuranoside 
• 532-20-7 D-Ribose 
• 16838-89-4 2,3,5-tri-O-benzyl-D-ribofuranose 
• 108-24-7 acetic anhydride 

Downstream Products

• 191340-56-4 1-O-cyclohexyl-2,3,5-tri-O-benzyl-D-ribofuranose 
• 1174234-12-8 3,4-Bis-benzyloxy-5-benzyloxymethyl-tetrahydro-furan-2-ol 
• 82267-01-4 (2S,3S,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)tetrahydrofuran-2-carbonitrile 
• 86883-48-9 methyl 6-O-(2,3,5-tri-O-benzyl-β-D-ribofuranosyl)-2,3,4-tri-O-benzyl-α-D-glucopyranoside 
• 1333119-42-8 4-penten-1-yl 2,3,5-tri-O-benzyl-β-D-ribofuranoside 

Relevant academic research and scientific papers

ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF

Disclosed herein are nucleoside compounds and derivatives thereof, pharmaceutical compositions containing same, and their methods of synthesis. The compounds are useful in treating orthomyxovirus infections, such as influenza infections.

COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPASE

Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions involving Ran GTPase.

Synthesis of novel C4-linked C2-imidazole ribonucleoside phosphoramidite and its application to probing the catalytic mechanism of a ribozyme

The synthesis of a novel C4-linked C2-imidazole ribonucleoside phosphoramidite (ICN-C2-PA 1) with a two-carbon linker between imidazole and ribose moieties is described. In the phosphoramidite, POM and 2-cyanoethyl groups were select